(N = 108)
|Metastatic CSCC, n||75|
|Locally advanced CSCC, n||33|
|Median age, years (range)||71 (38-96)|
|ECOG Performance Status, %|
CSCC, cutaneous squamous cell carcinoma;
ECOG, Eastern Cooperative Oncology Group.
of patients received LIBTAYO as first-line systemic therapy
of patients had received prior cancer-related surgery
of patients had received any prior radiotherapy
of metastatic patients had distant metastasis
of metastatic patients had only nodal metastasis
Programmed death ligand 1 (PD-L1) testing is not
required before starting LIBTAYO.